Three structurally related but functionally different serpins from horse plasma were isolated and characterized. In spite of their identical N-terminal sequences, which show some similarity to that of human ac-proteinase inhibitor, the reactivecentre loops of each of these proteins show extensive variation. Only inhibitor I, with a P1 methionine residue, resembles human al-PI with regard to (a) similarity of amino acid sequence in the vicinity of the reactive-site peptide bond, (b) broad inhibitory specificity, (c) sensitivity to oxidative inactivation and (d) high rate of reactivity with neutrophil elastase(s). Inhibitor II, with a P1 arginine residue, is an exclusive trypsin inhibitor, and inhibitor III is an oxidation-resistant slowreacting elastase inhibitor with a P, alanine residue. Comparison of association rate constants for the inhibition of horse neutrophil elastases by the three inhibitors indicates that only inhibitor I is likely to be physiologically important in the regulation of these enzymes.
INTRODUCTION
Human az-proteinase inhibitor (a1-PI) is a plasma glycoprotein which is responsible for more than 90% of the trypsin-and elastase-inhibitory capacity in this fluid [1] . The pathophysiological importance of this inhibitor arises from the fact that an inborn deficiency in its secretion (ZZ phenotype) can lead to the development of familial emphysema [2] . The aetiology of this disease is well established and results from an imbalance between available al-PI and leucocyte elastase in the lower respiratory tract [3] , favouring uncontrolled proteolysis by the latter. It is also believed that inactivation, by oxidation of the P1 methionine residue of al-PI, can result in a functional imbalance between inhibitor and elastase in normal individuals. Indeed, the strong correlation between inhalation of cigarette smoke and the risk of emphysema is almost certainly due to oxidative inactivation of al-PI by components produced either directly from the smoke or by neutrophils attracted to the lung [4] [5] [6] [7] .
Besides man, the only other animal species known to suffer from spontaneous chronic lung disease is the horse [8] [9] [10] . This animal has a high level of elastase-inhibitory activity in both its plasma and the cytosol of its neutrophils, the latter having been found to possess an oxidation-resistant elastase inhibitor [11, 12] . In contrast, the sheep, which has often been used as an animal model of human lung disease, has low plasma antielastase activity and low elastase activity in its neutrophils. We have recently demonstrated that nearly 60 % of horse plasma elastaseinhibitory activity is also oxidation-resistant [13] , suggesting that more than one type of inhibitor is present in this fluid. Functional heterogeneity ofmultiple forms ofhorse al-PI has been previously reported [14, 15] , together with the suggestion that the deficiency of a specific elastase isoinhibitor could be responsible for the development of lung disease in the horse [14] . In the present paper we describe the isolation of three different functional inhibitors from horse plasma, two of which can inactivate horse neutrophil elastase(s), together with reactive-site loop amino acid sequences and kinetics of the interaction of each with different proteinases.
MATERIALS AND METHODS

Materials
Horse leucocyte elastases 2A and 2B and human neutrophil elastase were purified according to previously published procedures [16, 17] . Human thrombin was a gift from Dr. J. Fenton (New York State Health Department, Albany, NY, U.S.A.). All other enzymes and chemicals of at least analytical grade were from Sigma Chemical Co.
Purification of horse plasma inhibitors
The purification scheme for the isolation of horse plasma inhibitors was based, initially, on the procedure described by Pannel et al. [18] for the isolation of human a1-PI. It consisted of the following steps: (1) (NH4)2 S04 precipitation; (2) Cibacron Blue-Sepharose chromatography; (3) DEAE-cellulose (DE-52) ion-exchange chromatography at pH 6.8 and rechromatography at pH 8.0; (4) gel filtration on Sephadex G-100. Homogeneity of the inhibitor was checked by both SDS/PAGE and crossed immunoelectrophoresis against rabbit antiserum to whole horse plasma.
The separation of different isoinhibitors was obtained by ionexchange chromatography in the Pharmacia f.p.l.c. system with a Mono Q column. To distinguish between different forms of horse inhibitors, the inhibitory capacity for trypsin and human leucocyte elastase was determined in each fraction, both before and after N-chlorosuccinimide treatment, and inhibitory activity was related to (Table 1 ). This suggests that these proteins are very closely related to each other and that their individual specificities must be due to structural differences in other areas, but especially in the reactive-site loop.
Reactive-site structure When trypsin in complex with its inhibitor (inhibitor II) was submitted to sequencing, three residues were obtained in each cycle ( Table 2) . Two of these were due to trypsin and native inhibitor. The third sequence was as follows:
Thr-Leu-Leu-His-Thr-Asn (inhibitor II) These data indicate that complex-formation with trypsin occurred by attack of the enzyme at an Xaa-Thr reactive-site peptide bond. Similar results were obtained when the elastaseelastase inhibitor complexes were sequenced. Besides the N-terminal sequences of enzyme and native inhibitor, the new sequences were determined to be as follows:
Ser-Leu-Pro-Pro-Glu-Leu-Glu-Phe-Asn-Arg-Pro-Phe (inhibitor I)
Thr-Leu-Leu-Leu-Asp-Asn-Val-Glu-Phe-Asn-Arg-Pro-Phe (inhibitor III) These data suggest cleavage at Xaa-Ser and Xaa-Thr reactive sites for inhibitors I and III respectively.
Incubation of inhibitor I, II or III with catalytic amounts of S. aureus V8 proteinase and inhibitor II or III with clostripain resulted in rapid loss of inhibitory activity (Figs. lb and la respectively), presumably because of limited proteolysis at or near the reactive site. Significantly, there was a major difference in this sensitivity for proteolytic inactivation among the three inhibitors. Specifically, inhibitor I was completely resistant to inactivation by clostripain (Fig. la) but was most sensitive for proteolytic cleavage by the V8 proteinase (Fig. Ib) . This indicates that considerable structural differences around the reactive site of the horse inhibitor must exist in spite of identical N-terminal sequences.
When V8-proteinase-treated inhibitors were directly submitted to N-terminal sequence analysis, three residues were obtained in each step up to ten cycles, because of cleavage in the reactive-site loop as well as between residues 10 and II (Glu-Ala) of the native proteins. However, sequencing of f.p.l.c.-purified modified forms of inhibitors gave only two parallel sequences (Table 3) , the N-terminal decapeptide having been separated. These data enabled us to determine the reactive sites of all three inhibitors by overlap with those described above ( Table 2) Inhibitor III (oxidation-resistant elastase inhibitor): (Glu)-Arg-Pro-ALA-THR-Leu-Leu-Leu-Asp-Asn-Val-Glu-PheAsn-Arg-Pro-PheThus MET-SER, ARG-THR and ALA-THR represent the P1-Pi' residues in the inhibitor reactive site of inhibitors I, II and III respectively. Owing to the limited specificity of the V8 proteinase [22] , it is expected that in all cases inhibitor inactivation occurred by cleavage at a Glu-Xaa peptide bond. The lack of an arginine residue in the reactive-site region of the oxidationsensitive elastase inhibitor most probably explains the resistance of this inhibitor to proteolytic inactivation by clostripain.
Association rate constants for native and oxidized inhibitors
Comparison of association rate constants revealed few significant conclusions. Only inhibitor I, which accounts for 40% of the elastase-inhibitory activity in plasma [14] , was efficient against two major horse leucocyte elastases (K... > I07 M-* s-1). The remaining elastase-inhibitory activity is presumably due to inhibitor III, which had relatively low association rates with both of the two horse enzymes (Table 4) . These weak association rate constants are somewhat surprising, since the P1 position of the reactive site of inhibitor III is occupied by an alanine residue, which should be highly suitable for complexformation with serine elastolytic enzymes. Inhibitor II, with a P1 arginine, was, as expected, exclusively a trypsin inhibitor.
The oxidation of inhibitors in the presence of a 30-fold molar excess ofN-chlorosuccinimide led to inactivation ofonly inhibitor I (Fig. 2) . Unlike the oxidation of human a,-PI, oxidative modification of this inhibitor resulted in a loss of all inhibitory activity (Table 4) , probably because of modification of the two methionine residues at the P1 and P4 positions.
DISCUSSION
Horse plasma al-PI has been purified and partially characterized in four independent laboratories [23] [24] [25] [26] [27] [28] . Although it was obvious that such preparations contained at least two electrophoretically different but immunologically identical isoinhibitors [14, 25, 27] , no real attempt was made to separate and characterize the different forms. Even greater heterogeneity of the horse proteinase-inhibitory system has been shown by a combination of polyacrylamide-gel isoelectric focusing and polyacrylamide-gel pore gradient electrophoresis [15, [28] [29] [30] . From our preparation of horse al-PI we were able to separate and characterize three different inhibitors. These were found to differ from each other with regard to: (a) sensitivity to proteolytic cleavage by bacterial proteinases; (b) sensitivity to oxidative inactivation; (c) inhibitory specificity. On the other hand, all three inhibitors had an identical N-terminal sequence up to 32 residues, which suggested that they were also closely related to each other (Table 1) .
Despite this remarkable identity at the N-terminus, horse a,-PI isoforms differ significantly within the reactive-site loop (Table 5 ). In this region only inhibitor I demonstrates significant similarity to human a,-PI. Indeed, eight of ten residues between the P5 and P5' subsites of the reactive site are identical.
This inhibitor, after oxidation, loses all activity against elastases or trypsin (Table 4) , whereas human al-PI is still active, slowly forming less stable inhibitory complexes with target proteinases [31, 32] . This difference might be explained by oxidation of two methionine residues at the P4 and P1 positions in the horse inhibitor, in comparison with that of the P8 and P1 residues in human a.-PI. A second difference between these two inhibitors is with regard to pancreatic elastase inhibition, the horse inhibitor being ineffective against this enzyme. Although it is clear that the P1 residue dictates serpin specificity which is further modulated by adjacent residues, including those in P1' positions [33] , it may well be that, in the case of the horse inhibitor, specificity might Vol. 274 469 also involve the P4 and P2' subsites of the reactive centre, which are different for these two elastase inhibitors.
The reactive-site amino acid sequence of inhibitor II had, as was expected from its specificity, a P1 arginine residue. A comparison of the amino acid sequence at the reactive centre of this inhibitor with human ax1-PI reveals some similarity, but major differences occur at or near the P1 residue. Surprisingly, inhibitor II and human Cl inhibitor show significant sequence similarity in the vicinity of their reactive sites, including an Arg-Thr-Leu-Leu sequence between the P1 and P3' positions. The physiological function of horse inhibitor II is obscure at the moment, and it would be useful to study the interactions of this protein with the known target proteinases for Cl inhibitor.
Inhibitor III was determined to have a P1 alanine residue, and this explains its resistance to oxidative inactivation [34] . Although this inhibitor forms complexes with pig pancreatic elastase, as well as with those from horse and human neutrophils, inhibition rates are rather low (Table 4 ). This is difficult to explain, since other inhibitors with a P1 alanine residue [12, 34, 35] react with mammalian elastolytic enzymes very rapidly. Once more, this reiterates the importance of other residues in the vicinity of the reactive-site peptide bond, or elsewhere, in determining serpin specificity.
The pig [36, 37] , human [38, 39] , horse [40, 41] , mouse and rat [42] have multiple proteinase-inhibitor-related gene complexes. Indeed, three different contrapsin-related cDNA clones have been described in rodents [43, 44] , although nothing is known about their expression in vivo. In the horse, however, three forms of a,-PI are expressed and present in plasma, and it is likely that genes encoding them were created by ancestral al-PI-related gene duplication followed by accelerated evolution of that part of the gene containing the reactive site, as was shown for the three rodent proteinase inhibitors [43] . It is postulated that mutations within the reactive-site loop are being rapidly fixed by positive Darwinian selection based on modification of inhibitory activity [43] or based on modified cleavage susceptibility [45] . It is thus likely that there will be great evolutionary pressure for the conservation of mutational changes that provide resistance to loop cleavage by pathogenic proteinases.
In the case of the horse, such guided evolution has created an oxidation-resistant elastase inhibitor (inhibitor III). Since oxidative inactivation of human al-PI by oxidants released by activated neutrophils is thought to be important in uncontrolled lung elastin degradation, ultimately leading to the development of emphysema [46] [47] [48] , having inhibitor III would appear to be a distinct advantage for the horse. However, a close look at the association rate constants (Table 4 ) and calculation of a delay time [21] for elastase inhibition in horse plasma (1.0 s for horse elastase 2B, 15 
